WOLFGANG WINKELMAYER to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Randomized Controlled Trials as Topic.
Connection Strength
0.607
-
Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int. 2018 12; 94(6):1053-1068.
Score: 0.111
-
Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. Am J Kidney Dis. 2018 07; 72(1):62-74.
Score: 0.106
-
Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. Kidney Int. 2016 08; 90(2):411-421.
Score: 0.094
-
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul; 66(1):69-74.
Score: 0.086
-
Epidemiologic and statistical methods for comparative effectiveness research. Heart Fail Clin. 2013 Jan; 9(1):29-36.
Score: 0.073
-
Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. Am J Kidney Dis. 2009 Sep; 54(3):554-60.
Score: 0.058
-
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022 09; 97(9):1178-1188.
Score: 0.036
-
Fostering innovation, advancing patient safety: the kidney health initiative. Clin J Am Soc Nephrol. 2013 Sep; 8(9):1609-17.
Score: 0.019
-
Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation. 2005 Dec 13; 112(24):3745-53.
Score: 0.011
-
A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int. 2004 Sep; 66(3):1239-47.
Score: 0.010